News, reviews and podcasts from annual scientific meetings and symposiums around the world.
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with…
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall…
A secondary analysis of the phase II clinical trial NRG-RTOG 0424, which initially reported a 73.1%…
Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab…
Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab…
New research presented at the COSA ASM shows how increased utilisation of radiation therapy for…
Research presented at the Clinical Oncology Society of Australia’s Annual Scientific Meeting shows that poor…
Doctors who give advanced breast cancer patients just one estimate, such as 12 months, for…
Patients with advanced breast cancer that has spread to the skin are likely to cause…
A 10-year study of Australian men affected by prostate cancer has found significant numbers of…